search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Individually tailored elastic compression therapy after deep venous thrombosis (DVT).


- candidate number8642
- NTR NumberNTR2597
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR9-nov-2010
- Secondary IDs171102007 / NL32073.068.10; ZonMw / METC MUMC
- Public TitleIndividually tailored elastic compression therapy after deep venous thrombosis (DVT).
- Scientific TitleIndividually tailored elastic compression therapy after deep venous thrombosis in relation to the incidence of post thrombotic .syndrome. A multi-center, randomized, allocation concealed, single blinded clinical trial in patients with acute proximal DVT with a follow-up of 24 months.
- ACRONYMAcronym: The Ideal DVT study (Individualized duration of elastic compression therapy against long-term duration of therapy).
- hypothesisTailoring elastic compression therapy to individual patients needs will not lead to an increased incidence of the post thrombotic syndrome, substantial costs will be saved and the quality of life of individual patients will improve.
- Healt Condition(s) or Problem(s) studiedDeep vein thrombosis , Elastic stockings , Postthrombotic syndrome
- Inclusion criteria1. Legal age (18 yrs);
2. Informed consent;
3. Acute objectively documented DVT of the leg;
4. Adequate anticoagulation.
- Exclusion criteria1. Previous DVT in the affected leg;
2. Recurrent DVT in the first 6 months following inclusion;
3. Preexistent venous insufficiency ( skin signs C4-C6 on CEAP score or requiring ECS therapy);
4. Contraindication for elastic compression therapy ( arterial insufficiency);
5. Active thrombolysis;
6. Life expectancy < 6 months.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingSingle
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 15-mrt-2011
- planned closingdate15-mrt-2016
- Target number of participants864
- InterventionsElastic compression therapy with a standard duration of 24 months compared to individually tailored duration of elastic compression therapy, following an initial therapeutic period of 6 months, based on signs and symptoms according to the Villalta scale.
- Primary outcomeThe occurrence of PTS at 24 months after the event of acute DVT (the observers will be blinded to the allocated treatment arm).
- Secondary outcome1. Health Related Quality of Life (HRQOL), will be measured by questionnaires SF-36, EuroQol-5D, Veines-Qol Dutch translated (time point baseline, 3, 6, 12 and 24 months);
2. Recurrent venous thrombosis (time point 24 months);
3. Mortality due to venous thrombosis (time point 24 months);
4. Costs will include direct costs (e.g. medical therapy) and indirect costs (e.g. travel) and will be measured by case record forms, hospital data and 5 retrospective cost-questionnaires (time point 3, 6, 12, 24 months);
5. Patient Preference will be elicited by conducting a discrete choice experiment (DCE) at time point 12 months.
- Timepoints1. Percentage PTS at 24 months (assessments performed at 3, 6, 12 and 24 months);
2. Data on HRQOL at baseline, 3, 6, 12 en 24 months;
3. Patient preference at 12 months.
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESMD. PhD. MpH. A.J. Cate-Hoek, ten
- CONTACT for SCIENTIFIC QUERIESMD. PhD. MpH. A.J. Cate-Hoek, ten
- Sponsor/Initiator Maastricht University Medical Center (MUMC+)
- Funding
(Source(s) of Monetary or Material Support)
ZON-MW, The Netherlands Organization for Health Research and Development
- Publicationspilot data; J Vasc Surg. 2010 Jul;52(1):132-8).
- Brief summaryRationale:
In the Netherlands, 25.000 patients each year are diagnosed with Deep Venous Thrombosis (DVT). Elastic compression stocking (ECS) therapy reduces the incidence of post thrombotic syndrome (PTS) following DVT from 50% without ECS to 20-30% after ECS therapy for two years. It is however unclear whether all patients benefit to the same extent from this therapy or what the optimal duration of ECS therapy for individual patients should be. ECS therapy is not only costly, inconvenient and demanding but sometimes also even debilitating. Substantial costs could be saved by tailoring therapy to individual needs and the quality of life for individual patients can be expected to improve.

Objective:
To assess the costs and effects of tailoring the duration of ECS therapy after DVT to individual patients needs.

Study design:
A multi-center, randomized, allocation concealed, single-blinded clinical trial in patients with acute proximal DVT with a follow-up of 24 months.

Study population:
Consecutive, adult outpatients after acute proximal DVT who present themselves at one of the participating centers.

Intervention:
ECS therapy with a standard duration of 24 months versus tailored ECS therapy following an initial therapeutic period of 6 months, based on signs and symptoms according to a Villalta scale.

Main study parameters/endpoints:
Primary outcome: Percentage of patients with PTS at two year follow-up.
Secondary outcomes: 1. Health Related Quality of Life (HRQOL), 2. Recurrent venous thrombosis,3. Mortality due to venous thrombosis, 4. Costs and 5. Patient preference.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
The study burden for patients is kept to a minimum and will comprise of regular visits and questionnaires. The study burden for clinicians is low. Patients will be seen at regular intervals (3, 6, 12 and 24 months) at the outpatient clinic. Patients will receive questionnaires preceding their visits. A clinical score to assess post thrombotic complaints will be performed at the out clinic visits. Based on our previous findings we expect that due to individual tailoring of therapy, 50% of patients will need ECS therapy for a period of maximum 12 months, instead of 24 months. HRQOL may be positively affected. Shorter therapy duration is not anticipated to have a negative implication on the incidence of PTS during the 24 months period of follow-up (pilot data; J Vasc Surg. 2010 Jul;52(1):132-8).
- Main changes (audit trail)
- RECORD9-nov-2010 - 20-nov-2010


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl